top of page
Browse by category
Search
Study examines California's legislative efforts on obesity and finds critical insights into policy trends and success rates over two decades
A recent multi-campus study, co-led by public health researchers from University of California (UC) Irvine and UC Merced, is the first of...
Allurion launches AllurionMeds first AI-native compounded GLP-1 program
Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss...
COMBINE trial: Glucose clamp technique as part of a new type 2 diabetes research trial
Researchers at Leicester Diabetes Centre (LDC) have successfully started using the glucose clamp technique as part of a new type 2...
Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...
More than half of US adults could benefit from GLP-1 medications
More than half of US adults, an estimated that 137 million people, are eligible for semagludtide for weight loss, diabetes management, or...
BMS safe and effective for patients living with severe obesity
Bariatric and metabolic surgery (BMS) is largely safe and effective for patients who are living with severe obesity, according to a team...
GLP-1 RAs found to shrink heart muscle in mice and human cells
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with shrinking the human heart and other muscles, according to a...
Ingestible capsule pumps drugs directly into the walls of the GI tract
Massachusetts Institute of Technology (MIT) and Novo Nordisk researchers have developed an ingestible capsule that releases a burst of...
Tracking leptin pulse patterns offers a potential clue to understanding obesity
Researchers at NYU Tandon School of Engineering have utilised a probabilistic physiological modelling approach to investigate the pulse...
ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH
Results from part 1 of the ongoing Phase 3 ESSENCE trial - evaluating the effect of once-weekly subcutaneous semaglutide 2.4mg on liver...
Browse by tag
bottom of page